---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Pathophysiology"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Pathophysiology. Topics: Neuromuscular junction: reduced acetylcholine receptors and sodium channels; AChR antibodies: complement fixation, antigenic modulation, and receptor blockade; Complement: classical pathway initiation at the endplate; Complement: deposition at the endplate in patients; 4 further topics. 8 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/pathophysiology"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### Neuromuscular junction: reduced acetylcholine receptors and sodium channels

> “In addition, there is a reduction in the number of AChRs and voltage-gated sodium channels as the result of complement-related injury to the postsynaptic membrane in MG.”
> “The resultant inefficient neuromuscular transmission is reflected in decremental response in the amplitude of compound muscle action potential (CMAP) during repetitive nerve stimulation (RNS) and abnormal jitter or blocking in single fiber EMG”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="topic-2.2.1.4-2"></a>

### AChR antibodies: complement fixation, antigenic modulation, and receptor blockade

> “The predominant mechanism is the binding of the antibody and activation of the complement cascade, leading to the formation of the membrane attack complex (MAC), which causes damage of the postsynaptic membrane and destruction of synaptic folds which contain AChRs and associated proteins, including voltage-gated sodium channels”
> “Other mechanisms of pathogenicity include: (1) antigenic modulation by the binding and crosslinking of AChRs, leading to increased endocytosis and degradation [37]; and (2) the impairment of AChR function, either by the blocking of ACh binding to the receptor [38] or the prevention of channel opening”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

> “Anti-AChR autoantibodies belong to the IgG1 and IgG3 subclasses, that are the strongest activators of the complement system.”
> “Indeed, pathogenicity of these autoantibodies, but not that of anti-MuSK antibodies that belong to IgG4, is mainly due to complement fixation at the NMJ ultimately leading to postsynaptic membrane destruction and impairment of the neuromuscular transmission”

Source: [Cavalcante et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187261/)

<a id="topic-2.2.1.4-3"></a>

### Complement: classical pathway initiation at the endplate

> “In MG, complement-mediated damage of the NMJ occurs via the classical complement pathway, which starts with C1q binding to the Fc domain of the autoantibodies.”
> “Critical steps of the complement cascade are then the cleavage of C3 into C3a and C3b, and of C5 in C5a and C5b, the latter leading to the formation of the membrane attack complex (MAC, C5bC6C7C8C9 also known as C5b-9) that causes focal lysis of the post-synaptic membrane, disruption of post-junctional folds, and ultimately reduction of functional AChRs”

Source: [Cavalcante et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187261/)

> “In MG, the classical pathway is involved by the initiation of the antigen/antibody complex being recognized by C1q.”
> “The C1q forms a pentameric complex with the C1r2C1s2 serine protease tetramer.”
> “C2 also becomes cleaved by C1s to form the C3 convertase (C4b2a).”

Source: [Kusner et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3531867/)

<a id="topic-2.2.1.4-4"></a>

### Complement: deposition at the endplate in patients

> “In muscle biopsies from MG patients, IgG and C3 deposition was localized at identical sites of post-synaptic membrane, and specifically on debris of junctional folds in the synaptic clefts and disintegrating junctional folds”
> “Deposition of C9, the main component of the final and stable MAC, was also observed at the MG end plate regions, with the most intense depositions associated with the destroyed NMJs, indicating that NMJ loss may be largely due to complement activation”

Source: [Cavalcante et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187261/)

> “Patients with anti-AChR+ MG have autoantibodies and MACs present at NMJs.”
> “Damaged NMJs are associated with more severe disease, fewer AChRs, and MACs in synaptic debris.”

Source: [Howard (2018)](https://pubmed.ncbi.nlm.nih.gov/29266249/)

<a id="topic-2.2.1.4-5"></a>

### Complement: evidence from experimental autoimmune myasthenia gravis

> “Mice deficient in C3 and C4 demonstrate reduced clinical scores compared to their wild-type littermates during the course of active EAMG, with C3-knockout mice showing no signs of weakness.”
> “Complement-deficient EAMG animals showed a preservation of AChR density at the neuromuscular junction.”
> “C5-deficient mice demonstrated reduced incidence of disease compared to the C5-sufficient mice.”

Source: [Kusner et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3531867/)

> “Studies in animals lacking specific complement proteins have confirmed that MAC formation is required to induce experimental autoimmune MG (EAMG) and NMJ damage.”
> “Complement inhibition in EAMG models can prevent disease induction and reverse its progression.”

Source: [Howard (2018)](https://pubmed.ncbi.nlm.nih.gov/29266249/)

<a id="topic-2.2.1.4-6"></a>

### Complement: C1s and classical pathway activation in patients

> “The C1-inhibitor (C1-INH) regulates the classical pathway and is a promising marker in other autoimmune disorders.”
> “Serum and plasma C1s-C1-INH levels were higher in MG patients than in matched healthy controls, supporting early classical pathway activation in most MG patients.”
> “These findings allow prospective validation studies of activated C1s as a putative treatment target and potential accompanying biomarker in MG.”

Source: [Huang et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39255718/)

> “Circulating complement protein profile may be used as a biomarker for evaluating patient-specific complement activation: (i) Romi and colleagues found reduced C3 and C4 serum levels in AChR-MG patients with high autoantibody titers, indicating increased in vivo complement consumption”

Source: [Cavalcante et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187261/)

<a id="topic-2.2.1.4-7"></a>

### Complement: heterogeneity of complement dependence and response to C5 inhibition

> “By means of this system, they observed a subset of AChR-MG patients with high complement activity, who are likely patients in whom complement activation is the major disease mechanism, whereas the remaining patients showed low activity, reflecting possible complement-independent autoantibody-mediated mechanisms of NMJ damage”

Source: [Cavalcante et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187261/)

> “To date, all FDA-approved drugs in this category focus on targeting the C5 convertase enzyme.”
> “It is important to note that in MG there is no evidence suggesting a role for C5a in the disease.”
> “There remain upward of thirty percent of patients who do not benefit from complement inhibition, which demonstrates the importance of other mechanisms of autoantibody action.”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

<a id="topic-2.2.1.4-8"></a>

### MuSK and LRP4 antibodies: complement-independent mechanisms

> “MuSK antibodies belong mainly to the IgG4 subclass.”
> “They do not fix complement and are not strong activators of cell-mediated cytotoxicity”
> “The mechanism by which MuSK antibodies exert their pathogenic effect on the neuromuscular junction is via binding to the Ig-like domain of the protein, preventing its phosphorylation, and subsequently disrupting the Agrin-Lrp4-MuSK-Dok-7 signaling pathway.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

> “The LRP4 antibodies are primarily IgG1 and IgG2 subtypes and follow similar clinical presentation to a mild form of early-onset MG (22), inhibit clustering of AChR, and appear not to strongly activate complement”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
